Last updated on December 2013

Phase IIB Clinical Trial of Hamsa-1 in Metastatic Castration Resistant Prostate Cancer (CRPC)

Brief description of study

Hamsa-1™ is an anti-angiogenic drug combination designed for the treatment of cancer. The investigational product Hamsa-1™ comprises of four well-known active components. The therapy is administrated at a unique dosing regimen that was found to be effective and advantageous in terms of safety.The product is formulated as an oral suspension, conveniently administrated by the patients at home and not requiring medical staff assistance. This Phase IIb clinical trial aims to evaluate the efficacy of Hamsa-1™ for the treatment of metastatic Castration Resistant Prostate Cancer (CRPC) patients.

Clinical Study Identifier: NCT00684970

Find a site near you

Start Over

Sheba Medical Center

Tel Hashomer, Israel
  Connect »

Asaf Harofe Medical Center

Tzrifin, Israel
  Connect »